Hemangioma is the most common congenital benign vascular tumor in infants and young children, also known as infantilehemangioma in the literature, with a prevalence of 2% to 3% in newborns and a prevalence of 1:3 to 5 in females, with about 60% occurring in the head and neck. Hemangioma often appears within the first few days of life and appears as a small red spot in the early stage, followed by a rapid increase in size and rapid proliferation at the age of 1 month and 4-5 months. In 1982, Mulliken et al. proposed that hemangioma is a benign tumor characterized by proliferation of vascular endothelial cells, whereas vascular malformation is due to abnormal development of the embryonic vascular plexus, clearly distinguishing the two concepts of hemangioma and vascular malformation, which had been confused for many years, from a biological point of view; based on this classification, Waner and Suen called hemangiomas located in the dermis of the papillae superficial hemangiomas. The hemangioma located in the reticular dermis or subcutaneous tissue is called deep hemangioma, and the coexistence of the two types of hemangioma is called compound hemangioma. At present, this classification method has been widely accepted by domestic and foreign colleagues. According to the distribution characteristics, hemangiomas can be divided into focal and segmental. Unilocular focal hemangiomas have a typical proliferative and regressive phase, while multifocal hemangiomas may have multiple, small, scattered lesions involving the skin, liver, and gastrointestinal tract. If the number of hemangiomas is more than five, combined gastrointestinal and hepatic hemangiomas are likely and an abdominal ultrasound should be performed. Segmental hemangiomas are usually multiple, involving multiple subunits of the adjacent face, with indistinct demarcation, and are most often distributed along the trigeminal nerve area, especially in areas with beard (beard distribution). Based on the existing technical conditions and tools, we believe that the treatment of hemangiomas should be tailored to the age of the child, the size, location, and stage of the lesion. First, for red spots protruding from the skin found a few days after birth, treatment with drugs (oral propranolol, oral prednisone, topical timolol, etc.) and laser (lesions are more limited and superficial) should be taken as early as possible to block them from entering the rapid proliferative stage. Secondly, for hemangioma in the rapid proliferation stage, a step-by-step treatment should be adopted, i.e. drug therapy (oral propranolol, oral prednisone, local application of imiquimod, timolol, etc.) → injection therapy (local injection of hormone, pinyamycin, subcutaneous injection of alpha interferon, intravenous injection of cyclophosphamide, vincristine and other anticancer drugs, etc.) → surgery (if other treatments are ineffective). For small superficial skin hemangiomas, they can be treated with 0.5% timolol eye drops or 1% propranolol ointment in the early stage of proliferation. For some larger or deeper hemangiomas, a single treatment method is often ineffective, and a combination of treatment is needed, such as drug + laser treatment, and a combination of 2 or more drugs. In patients with severe hemangioma, it can be controlled by subcutaneous injection of interferon or intravenous injection of vincristine. The regressive hemangioma can wait for observation and make follow-up records. The residual lesions of hemangioma in the regression period, such as scar, deformity or pigmentation, can be treated by surgery or laser after 3.5 years of age.